Table 1

Data collection and time points for each CID

		Baseline or 0’ (fasting)	10’	15’	20’	30’	45’	60’	120’	180’	Next day
Primary endpoint	Subjective appetite (VAS for hunger, desire to eat, fullness, prospective food consumption)	X	X		X	X	X	X	X	X
Behavioural endpoints	Food preference and reward (LFPQ)	X			X
	Food cravings (CoEQ)	X
	Energy intake (24-hour dietary recall)										X
	Expected satiety	X (1 bite)
	Sensory-specific satiety	X (1 bite)	X
	Other appetite ratings (eg, thirst, nausea, bloating, appetite for something sweet/savoury)	X	X		X		X	X	X	X
Metabolic endpoints	Glucose and insulin	X	X	X		X		X	X
	Pancreatic polypeptide (PP)*	X	X	X		X
	GLP-1 and ghrelin	X				X		X
	Lipaemia (triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol)	X				X		X	X
Health endpoints	Liver function (ALT, AST, GGT, FL index, TyG index)	X							X
	HbA1c	CID1 and 6
	24-hour GI side effects (self-report)										X

*Time points for PP are earlier for yoghurt study.
ALT, alanine transaminase; AST, aspartate transaminase; CID, clinical investigation day; CoEQ, Control of Eating Questionnaire; FL index, fatty liver index; GGT, gamma-glutamyltransferase; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LFPQ, Leeds Food Preference Questionnaire; TyG index, triglycerides and glucose index; VAS, Visual Analogue Scale.